Latest News

In this episode, Amy Pearlman, MD, and Annah J. Vollstedt, MD, discuss emerging innovations in female pelvic medicine, including implantable tibial nerve stimulation, the role of pelvic floor physical therapy, and the future of incontinence care.

In this video, Nicole L. Miller, MD, FACS, discusses her approach to assessing patients after prior treatment failure for benign prostatic hyperplasia.

The addition of aglatimagene and valacyclovir to radiotherapy with or without ADT significantly improved disease-free survival in patients with intermediate- to high-risk localized prostate cancer.

Abigail Keller, MD, shares findings showing that nadofaragene firadenovec is associated with increased urine production during instillation compared with gemcitabine/docetaxel.

Clint D. Bahler, MD, reflects on key prostate cancer themes from AUA 2026, including the shift toward more personalized care.

In this episode of The UroOnc Minute, host Adam B. Weiner, MD, is joined by Chad Tang, MD, to discuss findings from the WOLVERINE meta-analysis, evaluating the effectiveness of metastasis-directed therapy for oligometastatic prostate cancer.

The primary end point—12-month DFS rate—was 80% (40/50 evaluable patients; 95% CI, 0.67-0.89), with 2 patients pending assessment and 3 not evaluable.

The pivotal trial is assessing the non-inferiority of the Separo Vessel Sealing System vs conventional mucosal cautery vasectomy.

Praful Ravi, MB, BChir, MRCP, discusses results from PSMAtrack, which assessed changes in PSMA-PET during initial systemic therapy for metastatic hormone-sensitive prostate cancer.

Titan Prime will be available in the US via a phased launch beginning in late 2026.

In this episode of Pearls & Perspectives, Amy Pearlman, MD, speaks with Tom Riester of LTR Pharma about the development of a novel intranasal therapy for erectile dysfunction, exploring its potential implications for sexual health, prostate cancer survivorship, and broader engagement in men's health care.

Pedro C. Barata, MD, MSc, FACP, discusses preliminary findings from the phase 3 ProstACT Global study evaluating 177Lu-rosopatamab plus standard of care for patients with mCRPC.

PSA50 response rates were 58.8% overall in Group A (72.7% at 10 MBq), 85.2% overall in Group B (100% at 10 MBq), and 52.5% overall in Group C (56.3% at 10 MBq).